Frankenius Equity AB - Feb 10, 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TLSI	Series A Convertible Preferred Stock	Other	$0	+206K	+89.5%	$0.00	436K	Feb 10, 2025	Common Stock	206K	$5.28	Direct	F1, F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023.
F2	Effective February 10, 2025, the Conversion Price of the 230,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock.
F3	After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 435,853 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election.
F4	All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.
F5	Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset.